The addition of progesterone to hormone replacement therapy (HRT) has been found to raise the risk of breast cancer. It is worth noting that taking low doses of progesterone alone, without oestrogen, does not seem to have the same effect on breast cancer risk. If used for less than 10 years, oestrogen-only HRT does not appear to increase the likelihood of developing breast cancer. However, it does increase the risk of endometrial cancer and should be avoided unless the patient has had a hysterectomy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Patients with stress incontinence who do not respond to pelvic floor muscle exercises and decline surgical intervention may be prescribed duloxetine, a serotonin-norepinephrine re-uptake inhibitor. This drug increases sphincter tone during the filling phase of urinary bladder function. However, before starting drug therapy, patients should try pelvic floor exercises and consider surgical intervention. Oxybutynin, an anticholinergic drug, is used to treat urge incontinence or symptoms of detrusor overactivity, but it is not recommended for frail, older women at risk of health deterioration. Desmopressin is the preferred drug treatment for children with nocturnal enuresis and may also be used for women with nocturia. Mirabegron is prescribed for patients with urge incontinence who cannot tolerate antimuscarinic/anticholinergic drugs. It is a beta-3 adrenergic agonist that relaxes the bladder.

Understanding Urinary Incontinence: Causes, Classification, and Management

Urinary incontinence (UI) is a common condition that affects around 4-5% of the population, with elderly females being more susceptible. Several risk factors contribute to UI, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. UI can be classified into different types, such as overactive bladder (OAB)/urge incontinence, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of UI involves completing bladder diaries for at least three days, vaginal examination, urine dipstick and culture, and urodynamic studies. Management of UI depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures such as retropubic mid-urethral tape procedures may be offered. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be used as an alternative to surgery.

In summary, understanding the causes, classification, and management of UI is crucial in providing appropriate care for patients. Early diagnosis and intervention can significantly improve the quality of life for those affected by this condition.

In cases where delayed placental delivery is observed in patients with placenta accreta, hysterectomy is the recommended treatment. This patient has a history of previous caesarean-section and pelvic inflammatory disease, indicating a likely placenta accreta, which was also diagnosed antenatally on ultrasound. The optimal management approach involves leaving the placenta in-situ and performing a hysterectomy to avoid potential haemorrhage from attempts to actively remove the placenta. While medical management with oxytocin and ergometrine may help manage post-partum haemorrhage, it is not a definitive treatment option. Cord traction is also unlikely to be effective as the placenta is abnormally implanted into the uterine wall. Waiting another 30 minutes is not advisable due to the risk of further bleeding.

Understanding Placenta Accreta

Placenta accreta is a condition where the placenta attaches to the myometrium instead of the decidua basalis, which can lead to postpartum hemorrhage. This condition is caused by a defective decidua basalis. There are three types of placenta accreta, which are categorized based on the degree of invasion. The first type is accreta, where the chorionic villi attach to the myometrium. The second type is increta, where the chorionic villi invade into the myometrium. The third type is percreta, where the chorionic villi invade through the perimetrium.

There are certain risk factors that increase the likelihood of developing placenta accreta, such as having a previous caesarean section or placenta previa. It is important for healthcare providers to be aware of these risk factors and monitor patients closely during pregnancy and delivery. Early detection and management of placenta accreta can help prevent complications and ensure the best possible outcome for both the mother and baby.

Although clinical features such as infrequent or absent ovulation and hyperandrogenism can suggest PCOS, NICE CKS recommends using specific diagnostic criteria. To diagnose PCOS, at least 2 out of 3 of the following criteria should be present: infrequent or no ovulation, signs of hyperandrogenism or elevated testosterone levels, and polycystic ovaries or increased ovarian volume on ultrasonography. It is important to note that a high BMI is not part of the diagnostic criteria, but signs of insulin resistance such as acanthosis nigricans may aid in diagnosis.

Polycystic ovary syndrome (PCOS) is a condition that affects a significant percentage of women of reproductive age. The exact cause of PCOS is not fully understood, but it is believed to involve both high levels of luteinizing hormone and hyperinsulinemia, with some overlap with the metabolic syndrome. PCOS is characterized by a range of symptoms, including subfertility and infertility, menstrual disturbances such as oligomenorrhea and amenorrhea, hirsutism, acne, obesity, and acanthosis nigricans.

To diagnose PCOS, a range of investigations may be performed, including pelvic ultrasound to detect multiple cysts on the ovaries. Other useful baseline investigations include FSH, LH, prolactin, TSH, testosterone, and sex hormone-binding globulin (SHBG). While a raised LH:FSH ratio was once considered a classical feature of PCOS, it is no longer thought to be useful in diagnosis. Testosterone may be normal or mildly elevated, but if markedly raised, other causes should be considered. SHBG is typically normal to low in women with PCOS, and impaired glucose tolerance should also be checked.

To formally diagnose PCOS, other conditions must first be excluded. The Rotterdam criteria state that a diagnosis of PCOS can be made if at least two of the following three criteria are present: infrequent or no ovulation, clinical and/or biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound scan. Polycystic ovaries are defined as the presence of at least 12 follicles measuring 2-9 mm in diameter in one or both ovaries, and/or an increased ovarian volume of over 10 cm³.

Genotypes and Associated Syndromes

There are several genotypes that can lead to different syndromes.

The genotype 46,XY can cause androgen insensitivity syndrome, where the patient is genotypically male but has complete resistance to testosterone. This results in the absence of male internal genitalia.

The genotype 46,XX is associated with a phenotypically normal female.

45,XO causes Turner syndrome, which is characterized by short stature, webbed neck, and streak gonads in girls.

47,XXY causes Klinefelter syndrome in males, which is characterized by atrophic testes, azoospermia, wide-set nipples, female distribution of body hair, and mild intellectual disability.

47,XYY causes tall stature, acne, and mild mental retardation in men. This genotype is also associated with aggressive behavior, but normal fertility.

Understanding Pelvic Conditions: Endometriosis, Adenomyosis, Fibroids, PCOS, and Chronic Pelvic Infection

Pelvic conditions can cause discomfort and pain for many women. Endometriosis is a common condition where tissue resembling the endometrium grows outside the endometrial cavity, often in the pelvis. Laparoscopy may reveal chocolate cysts and a thickened uterosacral ligament. Symptoms include continuous pelvic pain, colicky dysmenorrhoea, heavy menstrual loss, and clotting.

Adenomyosis occurs when endometrial tissue infiltrates the uterus muscle. Symptoms include dysmenorrhoea and menorrhagia. Laparoscopy may reveal subserosal endometrium, but no chocolate cysts or thickened uterosacral ligament.

Fibroids cause a bulky uterus on bimanual examination and menorrhagia, but not chocolate cysts or a bulky uterine ligament.

Polycystic ovarian syndrome (PCOS) symptoms include oligomenorrhoea, hirsutism, weight gain, and polycystic ovaries on ultrasound. Chocolate cysts and a thickened uterosacral ligament are not associated with PCOS.

Chronic pelvic infection presents with deep dyspareunia and chronic discharge, but not chocolate cysts or a thickened uterosacral ligament. Understanding these conditions can help women seek appropriate treatment and manage their symptoms.

This question involves two components. Firstly, the lady in question is seven weeks postpartum and has had unprotected intercourse after day 21, putting her at risk of pregnancy. Therefore, she must have a pregnancy test before receiving any form of contraception. Secondly, the safety of the combined oral contraceptive pill (COCP) at 7 weeks postpartum is being considered. While the COCP is contraindicated for breastfeeding women less than 6 weeks postpartum, this lady falls into the 6 weeks – 6 months postpartum category where the benefits of prescribing the COCP generally outweigh the risks. Therefore, it would be suitable to prescribe the COCP for her. It is important to note that even if a woman is exclusively breastfeeding, the lactational amenorrhea method (LAM) is only effective for up to 6 months postpartum. Additionally, while the progesterone only pill is a good form of contraception, it is not necessary to recommend it over the COCP in this case.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Pelvic inflammatory disease can raise the likelihood of an ectopic pregnancy occurring.

If a patient has a history of Chlamydia, it may have caused pelvic inflammatory disease before being diagnosed. Chlamydia can cause scarring of the fallopian tubes, subfertility, and an increased risk of ectopic pregnancy. Any condition that slows the egg’s movement to the uterus can lead to a higher risk of ectopic pregnancy.

While drinking excessively during pregnancy is not recommended due to the risk of neural tube defects and foetal alcohol syndrome, it is not linked to ectopic pregnancy. However, smoking is believed to increase the risk of ectopic pregnancy, highlighting the importance of asking about social history when advising patients who want to conceive.

A history of cervical ectropion is not a risk factor for ectopic pregnancy, but it can make a patient more prone to bleeding during pregnancy.

The previous use of an IUS will not increase the risk of an ectopic pregnancy. However, conceiving while an IUS is in place will raise the risk of this happening. This is due to the effect of slowing the ovum’s transit to the uterus.

A simple ovarian cyst will not increase the risk of an ectopic pregnancy. Large ovarian cysts can cause ovarian torsion, but a 3 cm cyst is not a cause for concern, and the patient does not have any signs or symptoms of ovarian torsion or ectopic pregnancy.

Understanding Ectopic Pregnancy: Incidence and Risk Factors

Ectopic pregnancy occurs when a fertilized egg implants outside the uterus, usually in the fallopian tubes. This condition is a serious medical emergency that requires immediate attention. According to epidemiological studies, ectopic pregnancy occurs in approximately 0.5% of all pregnancies.

Several risk factors can increase the likelihood of ectopic pregnancy. These include damage to the fallopian tubes due to pelvic inflammatory disease or surgery, a history of previous ectopic pregnancy, endometriosis, the use of intrauterine contraceptive devices (IUCDs), and the progesterone-only pill. In vitro fertilization (IVF) also increases the risk of ectopic pregnancy, with approximately 3% of IVF pregnancies resulting in ectopic implantation.

It is important to note that any factor that slows down the passage of the fertilized egg to the uterus can increase the risk of ectopic pregnancy. Early detection and prompt treatment are crucial in managing this condition and preventing serious complications.

According to the GMC guidelines in good medical practice for individuals aged 0-18 years, it is important to disclose information regarding any abusive or seriously harmful sexual activity involving a child or young person. This includes situations where the young person is too immature to understand or consent, there are significant differences in age, maturity, or power between sexual partners, the young person’s sexual partner holds a position of trust, force or the threat of force, emotional or psychological pressure, bribery or payment is used to engage in sexual activity or keep it secret, drugs or alcohol are used to influence a young person to engage in sexual activity, or the person involved is known to the police or child protection agencies for having abusive relationships with children or young people.

Failing to disclose this information or simply prescribing contraception and waiting for a review can put both the patient and other students at the boyfriend’s school in harm’s way due to his position of trust. While informing the boyfriend or his school may breach confidentiality and not address the issue of his job and relationship, it is important to take appropriate action to protect the safety and well-being of the young person involved.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

According to the GMC’s good medical practice advice, healthcare professionals can provide contraceptive, abortion, and STI advice and treatment to individuals aged 0-18 years without parental knowledge or consent if certain criteria are met. These include ensuring that the individual fully understands the advice and its implications, not persuading them to tell their parents or allowing you to do so, and determining that their physical or mental health is likely to suffer without such advice or treatment. Confidentiality should be maintained even if advice or treatment is not provided. In this scenario, the correct course of action is to prescribe the pill as the young girl fulfills the Fraser guidelines. Breaking confidentiality, as suggested in answer 4, is not recommended by the GMC guidelines. Therefore, the correct answer is 1.

When it comes to providing contraception to young people, there are legal and ethical considerations to take into account. In the UK, the age of consent for sexual activity is 16 years, but practitioners may still offer advice and contraception to young people they deem competent. The Fraser Guidelines are often used to assess a young person’s competence. Children under the age of 13 are considered unable to consent to sexual intercourse, and consultations regarding this age group should trigger child protection measures automatically.

It’s important to advise young people to have STI tests 2 and 12 weeks after an incident of unprotected sexual intercourse. Long-acting reversible contraceptive methods (LARCs) are often the best choice for young people, as they may be less reliable in remembering to take medication. However, there are concerns about the effect of progesterone-only injections (Depo-provera) on bone mineral density, and the UKMEC category of the IUS and IUD is 2 for women under the age of 20 years, meaning they may not be the best choice. The progesterone-only implant (Nexplanon) is therefore the LARC of choice for young people.

Injectable progesterone contraceptives should not be used in individuals with current breast cancer, as it is an absolute contraindication as per the UK medical eligibility criteria. Smoking more than 15 cigarettes a day is also a contraindication for the combined oral contraceptive pill, while migraine with aura is a contraindication for the same. Additionally, unexplained vaginal bleeding is a contraindication for starting the intrauterine device (IUD) or the intrauterine system (IUS).

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

How the Copper IUD Affects Different Parts of Sperm

The copper IUD is a popular form of birth control that works by preventing fertilization. It does this by affecting different parts of the sperm. The Golgi apparatus, which contributes to the acrosome of the sperm, is inhibited by the IUD, preventing capacitation. The mitochondria, which form the middle piece of the sperm, are not affected. The nucleus is also unaffected. Sperm do not have cell walls, so this is not a factor. Finally, the centrioles contribute to the flagellum of the sperm, but the copper IUD does not target this part of the sperm. Understanding how the copper IUD affects different parts of the sperm can help individuals make informed decisions about their birth control options.

Common Causes of Vaginal Discharge: Symptoms and Treatment

Bacterial vaginosis, Trichomonas vaginalis, Candidiasis, gonorrhoeae, and Pelvic inflammatory disease are some of the most common causes of vaginal discharge in women.

Bacterial vaginosis is caused by an overgrowth of anaerobic bacteria and loss of lactobacilli in the vagina. It presents with a grey-white, thin discharge with a fishy odour and an increased vaginal pH. Metronidazole is the treatment of choice.

Trichomonas vaginalis is a sexually transmitted infection that presents with a yellow-green discharge and an erythematosus cervix with a punctate exudate.

Candidiasis is a fungal infection associated with pruritus, burning, erythema, and oedema of the vestibule. The vaginal discharge is thick, curd-like, and white.

gonorrhoeae can be asymptomatic or present with abdominal pain, mucopurulent discharge, cervicitis, dyspareunia, or abnormal bleeding.

Pelvic inflammatory disease is the result of an ascending infection and presents with dyspareunia, lower abdominal pain, menstrual irregularities, irregular bleeding, and a blood stained, purulent vaginal discharge. Cervicitis and cervical excitation are also present.

Proper diagnosis and treatment are essential to prevent complications and improve the quality of life of affected women.

Not all hormonal contraceptives are contraindicated for patients assigned female at birth undergoing testosterone therapy. The combined oral contraceptive pill, which contains oestrogen, should be avoided as it may interfere with the effects of testosterone therapy. However, the copper intrauterine device and progesterone-only pill are acceptable options as they do not have any adverse effects on testosterone therapy. The vaginal ring, which also contains oestrogen, should also be avoided.

Contraceptive and Sexual Health Guidance for Transgender and Non-Binary Individuals

The Faculty of Sexual & Reproductive Healthcare has released guidance on contraceptive choices and sexual health for transgender and non-binary individuals. The guidance emphasizes the importance of sensitive communication and offering options that consider personal preferences, co-morbidities, and current medications or therapies.

For individuals engaging in vaginal sex where there may be a risk of pregnancy and/or sexually transmitted infections, condoms and dental dams are recommended. Cervical screening and human papillomavirus vaccinations should also be offered to sexually active individuals with a uterus. Those engaging in anal sex and rimming should be advised of the risk of hepatitis A & B and offered vaccinations. Individuals at risk of HIV transmission should be advised of the availability of pre-exposure prophylaxis and post-exposure prophylaxis as required.

For patients seeking permanent contraception, a fallopian tube occlusion or a vasectomy may be the most appropriate solution and neither would be affected by hormonal therapy. Testosterone therapy does not provide protection against pregnancy, and oestrogen-containing regimes are not recommended in patients undergoing testosterone therapy. Progesterone-only contraceptives are considered safe, and the intrauterine system and injections may also suspend menstruation. Non-hormonal intrauterine devices do not interact with hormonal regimes but can exacerbate menstrual bleeding.

In patients assigned male at birth, there may be a reduction or cessation of sperm production with certain therapies, but the variability of effects means they cannot be relied upon as a method of contraception. Condoms should be recommended in those patients engaging in vaginal sex wishing to avoid the risk of pregnancy. Emergency contraception may be required in patients assigned female at birth following unprotected vaginal intercourse, and either of the available oral emergency contraceptive options may be considered. The non-hormonal intrauterine device may also be an option, but it may have unacceptable side effects in some patients.

Overall, the guidance stresses the importance of individualized care and communication in contraceptive and sexual health decisions for transgender and non-binary individuals.

Diagnostic Tests for Abdominal Pain in Women of Childbearing Age

Abdominal pain in women of childbearing age requires a thorough diagnostic workup to rule out gynaecological emergencies such as ectopic pregnancy. The following diagnostic tests should be considered:

1. Pregnancy test (beta-human chorionic gonadotrophin (β-hCG)): This test should be the first step in the diagnostic workup to rule out ectopic pregnancy. A positive result requires urgent referral to the gynaecological team.

2. Full blood count: This test may indicate an ongoing infective process or other pathology, but a pregnancy test should be done first to rule out ectopic pregnancy.

3. Ultrasound of the abdomen and pelvis: Imaging may be useful in determining the cause of the pain, but a pregnancy test should be done first before considering imaging studies.

4. Urine culture and sensitivity: This test may be useful if a urinary tract infection and possible pyelonephritis are considered, but an ectopic pregnancy has to be ruled out first.

5. Erect chest X-ray: This test can show free air under the diaphragm, indicating a ruptured viscus and a surgical emergency. However, a pregnancy test should be done first to rule out ectopic pregnancy.

In conclusion, a thorough diagnostic workup is necessary to determine the cause of abdominal pain in women of childbearing age, with a pregnancy test being the first step to rule out gynaecological emergencies.

Possible Causes of Sudden Pelvic Pain: A Differential Diagnosis

Sudden pelvic pain can be a sign of various medical conditions. In this case, the patient’s symptoms suggest ovarian torsion, a condition that occurs when the ovary twists on its blood supply, causing ischemia and infarction. The resulting pain is severe, sharp, and sudden, often accompanied by tenderness and internal bleeding. However, other possible causes of sudden pelvic pain should also be considered.

Rectal diseases or trauma are unlikely to explain the patient’s current presentation. Similarly, while appendicitis can cause abdominal pain, fever, nausea, and anorexia, the pattern of pain is different, starting as dull pain around the belly button and becoming sharp and localized to the right lower quadrant over time. Rovsing’s sign, which is pain in the right lower quadrant when pressure is applied to the left lower quadrant, is often positive in appendicitis.

A ureteral stone can also cause sudden-onset pelvic and flank pain, but it is not associated with pelvic bleeding. Urinary tract stones typically cause colicky pain, which comes and goes in waves, rather than the unrelenting pain described by the patient.

Finally, a ruptured Fallopian tube can be a complication of an ectopic pregnancy, but the patient’s recent normal menstrual periods make this diagnosis less likely. In ectopic tubal pregnancy, the patient usually complains of amenorrhea, abnormal uterine bleeding, and pelvic pain of several days to weeks’ duration.

In summary, while ovarian torsion is a possible cause of the patient’s sudden pelvic pain, other conditions should also be considered and ruled out through further evaluation and testing.

Types of Epithelial Cells in the Female Reproductive System

The female reproductive system is composed of various types of epithelial cells that serve different functions. Here are some of the most common types of epithelial cells found in the female reproductive system:

1. Simple columnar cells – These cells are found in the endometrial lining and have a pseudostratified columnar appearance. They are often associated with endometrial carcinoma.

2. Glycogen-containing stratified squamous cells – These cells are found in the vagina and are responsible for producing glycogen, which helps maintain a healthy vaginal pH.

3. Cuboidal cells – These cells are found in the ovary and are responsible for producing and releasing eggs.

4. Stratified squamous cells – These cells are found in the cervix and provide protection against infections.

5. Columnar ciliated cells – These cells are located in the Fallopian tubes and are responsible for moving the egg from the ovary to the uterus.

Understanding the different types of epithelial cells in the female reproductive system can help in the diagnosis and treatment of various reproductive disorders.

For patients with menorrhagia who have completed their family and do not have any underlying pathology, pharmaceutical therapy is recommended. The first-line management for these patients, according to NICE CKS, is the Mirena coil, provided that long-term contraception with an intrauterine device is acceptable.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, also known as menorrhagia, is a condition where a woman experiences excessive blood loss during her menstrual cycle. While it was previously defined as total blood loss of over 80 ml per cycle, the management of menorrhagia now depends on the woman’s perception of what is excessive. In the past, hysterectomy was a common treatment for heavy periods, but the approach has changed significantly since the 1990s.

To manage menorrhagia, a full blood count should be performed in all women. If symptoms suggest a structural or histological abnormality, a routine transvaginal ultrasound scan should be arranged. For women who do not require contraception, mefenamic acid or tranexamic acid can be used. If there is no improvement, other drugs can be tried while awaiting referral.

For women who require contraception, options include the intrauterine system (Mirena), combined oral contraceptive pill, and long-acting progestogens. Norethisterone can also be used as a short-term option to rapidly stop heavy menstrual bleeding. The flowchart below shows the management of menorrhagia.

[Insert flowchart here]

The correct statement is that unopposed oestrogen increases the risk of endometrial cancer. Combined oestrogen and progesterone HRT can reduce the risk of endometrial cancer in patients with a uterus, while patients without a uterus should be prescribed oestrogen-only HRT as combined HRT is less well tolerated. The statement that unopposed oestrogen increases the risk of breast cancer is incorrect, as both types of HRT can increase the risk of breast cancer, with combined HRT potentially increasing the risk more than oestrogen-only. Additionally, the statement that unopposed oestrogen increases the risk of heart disease is incorrect, as oestrogen has a protective role in inhibiting the development of atherosclerosis, which can reduce the risk of heart disease. Finally, the statement that unopposed oestrogen increases the risk of osteoporosis is also incorrect, as HRT can be prescribed to prevent or treat osteoporosis in some patients and can reduce the risk of fracture instead of increasing it.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

If a woman requests it, the combined oral contraceptive pill can be prescribed 6 weeks after giving birth, even if she is breastfeeding. However, it is important to note that she can still become pregnant as early as day 21 postpartum. Therefore, if she has had unprotected sex during this time, a pregnancy test should be conducted before prescribing the pill.

After giving birth, women need to use contraception after 21 days. The progesterone-only pill (POP) can be started at any time postpartum, according to the FSRH. Additional contraception should be used for the first two days after day 21. A small amount of progesterone enters breast milk, but it is not harmful to the infant. On the other hand, the combined oral contraceptive pill (COCP) is absolutely contraindicated (UKMEC 4) if breastfeeding is less than six weeks post-partum. If breastfeeding is between six weeks and six months postpartum, it is a UKMEC 2. The COCP may reduce breast milk production in lactating mothers. It should not be used in the first 21 days due to the increased venous thromboembolism risk post-partum. After day 21, additional contraception should be used for the first seven days. The intrauterine device or intrauterine system can be inserted within 48 hours of childbirth or after four weeks.

The lactational amenorrhoea method (LAM) is 98% effective if the woman is fully breastfeeding (no supplementary feeds), amenorrhoeic, and less than six months post-partum. It is important to note that an inter-pregnancy interval of less than 12 months between childbirth and conceiving again is associated with an increased risk of preterm birth, low birth weight, and small for gestational age babies.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

To follow up on a positive hrHPV result with a cytologically normal sample, it is recommended to repeat the smear after 12 months as HPV can be naturally cleared by the immune system within this timeframe.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Management of Women after Treatment for Cervical Intra-epithelial Neoplasia

After treatment for cervical intra-epithelial neoplasia (CIN) at colposcopy, women undergo a repeat smear six months later to check for any residual disease. The management plan following this test of cure depends on the results.

HPV Test of Cure in Six Months, If Negative Recall in Three Years

If the test is negative for dyskaryosis and high-risk HPV (HR HPV), the woman is recalled in three years, regardless of her age. If the test remains negative at the three-year mark, she can return to routine screening based on her age group.

HPV Test of Cure in Six Months, If Negative Recall in Five Years

Even if the patient is 54 years old, women who have a negative HPV test of cure at six months are recalled for a smear three years later. If this is negative, she will then be returned to routine recall every five years.

HPV Test of Cure in Three Months, If Negative Recall in Five Years

The screening test should not be repeated at three months, as this is not enough time for the cervical tissue to heal. Reactive/healing changes in the cytological sample may give a false impression of dyskaryosis. Instead, a HPV test of cure is performed at six months, and if negative, the woman is recalled for routine screening every five years.

Refer Back to Routine Screening, Repeat in Three/Five Years

If the HPV test of cure is positive for HPV or there is evidence of moderate/severe dyskaryosis, the woman is referred back to colposcopy for further investigation. If the test is negative, she is referred back to routine screening and recalled in three or five years, depending on the scenario.

The combined oral contraceptive has only one absolute contraindication in a patient’s history, which is factor V Leiden (a UKMEC 4 level indicating an unacceptable health risk). Other elements of the patient’s history fall into UKMEC 3, where the disadvantages generally outweigh the benefits. However, it is important to note that some concurrent UKMEC 3 contraindications may become absolute contraindications when combined. Therefore, it is crucial to carefully study guidelines before prescribing.

The decision to prescribe the combined oral contraceptive pill is now based on the UK Medical Eligibility Criteria (UKMEC), which categorizes potential contraindications and cautions on a four-point scale. UKMEC 1 indicates no restrictions for use, while UKMEC 2 suggests that the benefits outweigh the risks. UKMEC 3 indicates that the disadvantages may outweigh the advantages, and UKMEC 4 represents an unacceptable health risk. Examples of UKMEC 3 conditions include controlled hypertension, a family history of thromboembolic disease in first-degree relatives under 45 years old, and current gallbladder disease. Examples of UKMEC 4 conditions include a history of thromboembolic disease or thrombogenic mutation, breast cancer, and uncontrolled hypertension. Diabetes mellitus diagnosed over 20 years ago is classified as UKMEC 3 or 4 depending on severity. In 2016, Breastfeeding between 6 weeks and 6 months postpartum was changed from UKMEC 3 to UKMEC 2.

The most appropriate investigation for a suspected ectopic pregnancy is a transvaginal ultrasound. In this case, the patient’s symptoms and examination findings suggest an ectopic pregnancy, making transvaginal ultrasound the investigation of choice. Transabdominal ultrasound is less sensitive and therefore not ideal. NAAT, which is used to detect chlamydia, is not relevant in this case as the patient’s history suggests a higher likelihood of ectopic pregnancy rather than infection. Laparoscopy, which is used to diagnose endometriosis, is not indicated based on the clinical presentation.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.

Co-cyprindiol is a medication that combines cyproterone acetate and ethinyl estradiol. It is commonly used to treat women with PCOS who have hirsutism and acne. Cyproterone acetate is an anti-androgen that reduces sebum production, leading to a reduction in acne and hirsutism. It also inhibits ovulation and induces regular withdrawal bleeds. However, it should not be used solely for contraception due to its higher risk of venous thromboembolism compared to other conventional contraceptives.

Topical retinoids are a first-line treatment for mild to moderate acne. They can be used alone or in combination with benzoyl peroxide.

Clomiphene citrate is a medication used to induce ovulation in women with PCOS who wish to conceive. It has been associated with increased rates of pregnancy.

Desogestrel is a progesterone-only pill that induces regular bleeds and provides contraception. However, its effect on improving acne and hirsutism is inferior to combination drugs like co-cyprindiol.

Isotretinoin is a medication that regulates epithelial cell growth and is used to treat severe acne resistant to other treatments. It is highly teratogenic and should only be started by an experienced dermatologist in secondary care. Adequate contraceptive cover is necessary, and patients should avoid conception for two years after completing treatment.

In the case of an inadequate smear test result, the patient will be advised to undergo a repeat test within 3 months. If the second test also yields an inadequate result, the patient will need to undergo colposcopy testing.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

The most probable diagnosis for this patient is ovarian torsion, which is common in women of reproductive age. Symptoms include pain in the iliac fossa that can spread to the loin, groin, or back, as well as nausea and vomiting. An adnexal mass may be present on examination, which is often caused by an ovarian cyst or neoplasm that has disrupted the ovary’s normal position and caused torsion. In some cases, a low-grade fever may also be present if ovarian necrosis has occurred.

It is important to rule out ectopic pregnancy as a differential diagnosis, which can be done with a pregnancy test regardless of reported contraception. Vaginal bleeding may help differentiate between the two conditions. However, since the patient’s menstrual period started 7 days ago and she uses condoms for contraception, ectopic pregnancy is less likely than ovarian torsion.

Appendicitis is also a possible cause of this presentation, but it typically presents with diffuse abdominal pain that later localizes to the right iliac fossa. In appendicitis, pain can be reproduced in the right iliac fossa by palpating the left iliac fossa (Rovsing’s sign), but left iliac fossa pain would not be the presenting symptom.

Mittelschmerz, which is mild pain in the right iliac fossa, could also be a possible cause, but it would not be associated with nausea and vomiting.

Causes of Pelvic Pain in Women

Pelvic pain is a common complaint among women, with primary dysmenorrhoea being the most frequent cause. Mittelschmerz, or pain during ovulation, may also occur. However, there are other conditions that can cause pelvic pain, which can be acute or chronic in nature.

Acute pelvic pain can be caused by conditions such as ectopic pregnancy, urinary tract infection, appendicitis, pelvic inflammatory disease, and ovarian torsion. Ectopic pregnancy is characterized by lower abdominal pain and vaginal bleeding in women with a history of 6-8 weeks of amenorrhoea. Urinary tract infection may cause dysuria and frequency, while appendicitis may present with pain in the central abdomen before localizing to the right iliac fossa. Pelvic inflammatory disease may cause pelvic pain, fever, deep dyspareunia, vaginal discharge, dysuria, and menstrual irregularities. Ovarian torsion, on the other hand, may cause sudden onset unilateral lower abdominal pain, nausea, vomiting, and a tender adnexal mass on examination.

Chronic pelvic pain, on the other hand, may be caused by conditions such as endometriosis, irritable bowel syndrome, ovarian cysts, and urogenital prolapse. Endometriosis is characterized by chronic pelvic pain, dysmenorrhoea, deep dyspareunia, and subfertility. Irritable bowel syndrome is a common condition that presents with abdominal pain, bloating, and change in bowel habit. Ovarian cysts may cause a dull ache that is intermittent or only occurs during intercourse, while urogenital prolapse may cause a sensation of pressure, heaviness, and urinary symptoms such as incontinence, frequency, and urgency.

In summary, pelvic pain in women can be caused by various conditions, both acute and chronic. It is important to seek medical attention if the pain is severe or persistent, or if there are other concerning symptoms present.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

Methotrexate is the preferred medication for treating ectopic pregnancy through medical management, provided the patient is willing to attend follow-up appointments.

Ectopic pregnancy is a serious condition that requires prompt investigation and management. Women who are stable are typically investigated and managed in an early pregnancy assessment unit, while those who are unstable should be referred to the emergency department. The investigation of choice for ectopic pregnancy is a transvaginal ultrasound, which will confirm the presence of a positive pregnancy test.

There are three ways to manage ectopic pregnancies: expectant management, medical management, and surgical management. The choice of management will depend on various criteria, such as the size of the ectopic pregnancy, whether it is ruptured or not, and the patient’s symptoms and hCG levels. Expectant management involves closely monitoring the patient over 48 hours, while medical management involves giving the patient methotrexate and requires follow-up. Surgical management can involve salpingectomy or salpingostomy, depending on the patient’s risk factors for infertility.

Salpingectomy is the first-line treatment for women without other risk factors for infertility, while salpingostomy should be considered for women with contralateral tube damage. However, around 1 in 5 women who undergo a salpingostomy require further treatment, such as methotrexate and/or a salpingectomy. It is important to carefully consider the patient’s individual circumstances and make a decision that will provide the best possible outcome.